

NEWS | HEALTHCARE & LIFE SCIENCES

GCCL Expands Asia-Pacific Clinical Trial Partnerships at Asia Bio Partnering Forum 2026

South Korean clinical sample analysis provider engages pharmaceutical, biotech and CRO partners across the region to expand central lab, bioanalytical and assay development services.

By **Ankit Kankar** | September 12, 2026



GCCL (Global Clinical Central Lab), a South Korea-based leading provider of clinical trial sample analysis, announced its participation as a Platinum Sponsor at Asia Bio Partnering Forum 2026 (ABP 2026), held in Singapore from August 31 to September 2.

Through a series of partnering meetings with global pharmaceutical and biotechnology companies, contract research organizations (CROs) and regional stakeholders, GCCL explored opportunities to expand its clinical sample analysis and assay development services across the Asia-Pacific region.

The company engaged with drug developers working across a broad range of therapeutic modalities, including mRNA and nucleic acid therapeutics, radiopharmaceuticals and antibody-based therapies. These discussions focused on evolving analytical requirements in global clinical development and potential opportunities for collaboration.

GCCL also met with executives from global CROs and Singapore-based pharmaceutical, diagnostics and clinical trial service companies to discuss existing partnerships and opportunities for further collaboration. In addition, the company engaged with a Singapore government-affiliated economic development organization to explore ways to support local biotech companies and strengthen connections within the regional life sciences ecosystem.

As a Platinum Sponsor, GCCL sponsored the official ABP 2026 Welcome Reception. Yoo-Hwa Choi, Head of Business Operations at GCCL, delivered welcome remarks and highlighted the company's capabilities in clinical sample analysis and its commitment to supporting global drug development.

At its exhibition booth, GCCL showcased its integrated Central Lab, Bioanalytical Lab and R&D Lab capabilities, which support clinical development from early- through late-stage trials. The company also held partnering discussions with pharmaceutical and biotechnology companies and related organizations from Korea, China, Japan, Singapore, Vietnam and Europe.

"ABP 2026 provided an important opportunity to engage directly with drug developers and global partners across the Asia-Pacific region and better understand their evolving analytical needs across increasingly diverse therapeutic modalities," said Yoo-Hwa Choi, Head of Business Operations at GCCL. "We will continue to build on these relationships and expand collaboration with global CROs and regional biotech companies as we strengthen GCCL's role as a trusted clinical development partner in Asia-Pacific."

ABP 2026 brought together approximately 650 pharmaceutical and biotechnology industry professionals, investors and life sciences stakeholders, with approximately 2,500 one-on-one partnering meetings held during the event.

Read online: <https://worldbusinesswatch.com/news/14/32/gccl-expands-asia-pacific-clinical-trial-partnerships-at-asia-bio-partnering-forum-2026.html>

© 2026 World Business Watch. All rights reserved.